Transcriptional regulation of pattern recognition receptors by JAK/STAT signaling, and the implications for disease pathogenesis

Journal of Interferon and Cytokine Research

Volumn 34, Issue 10, 2014, Pages 750-758

  Jenkins, Brendan John ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INFLAMMASOME; INTERLEUKIN 10; INTERLEUKIN 6; JANUS KINASE; JANUS KINASE 2 INHIBITOR; PATTERN RECOGNITION RECEPTOR; STAT PROTEIN; STAT3 PROTEIN; TOLL LIKE RECEPTOR;

APOPTOSIS; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE PRODUCTION; EXPERIMENTAL AUTOIMMUNE DISEASE; FEEDBACK SYSTEM; GENE EXPRESSION; GENE TARGETING; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE; MEDIATOR; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; TRANSCRIPTION REGULATION; ANIMAL; AUTOIMMUNE DISEASES; CARDIOVASCULAR DISEASES; GENETICS; METABOLIC DISEASES; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; AUTOIMMUNE DISEASES; CARDIOVASCULAR DISEASES; CYTOKINES; HUMANS; JANUS KINASES; METABOLIC DISEASES; MOLECULAR TARGETED THERAPY; RECEPTOR CROSS-TALK; RECEPTORS, PATTERN RECOGNITION; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 84927629289     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0081     Document Type: Review

References (102)

1. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. 2004. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20: 319-325.
2. Akira S, Uematsu S, Takeuchi O. 2006. Pathogen recognition and innate immunity. Cell 124: 783-801.
3. Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB, Herfarth HH, Jobin C, Ting JP. 2010. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 207: 1045-1056.
4. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, NIDDK IBD Genetics Consortium, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E, Belgian-French IBD Consortium, Wellcome Trust Case Control Consortium, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead SG, R., Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ. 2008. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 40: 955-962.
5. Bauer C, Duewell P, Mayer C, Lehr HA, Fitzgerald KA, Dauer M, Tschopp J, Endres S, Latz E, Schnurr M. 2010. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 59: 1192-1199.
6. Bode JG, Ehlting C, Häussinger D. 2012. The macrophage response towards LPS and its control through the p38 (MAPK)- STAT3 axis. Cell Signal 24: 1185-1194.
7. Bright JJ, Du C, Sriram S. 1999. Tyrphostin B42 inhibits IL-12- induced tyrosine phosphorylation and activation of Janus kinase-2 and prevents experimental allergic encephalomyelitis. J Immunol 162: 6255-6262.
8. Bruchard M, Mignot G, Derangère V, Chalmin F, Chevriaux A, Végran F, Boireau W, Simon B, Ryffel B, Connat JL, Kanellopoulos J, Martin F, Rébé C, Apetoh L, Ghiringhelli F. 2013. Chemotherapy-triggered cathepsin B release in myeloidderived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 19: 57-64.
9. Cader MZ, Kaser A. 2013. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut 62: 1653-1664.
10. Cario E. 2010. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis 16: 1583-1597.
11. Cario E, Gerken G, Podolsky DK. 2007. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 132: 1359-1374.
12. Chang L, Karin M. 2001. Mammalian MAP kinase signalling cascades. Nature 410: 37-40.
13. Chen GY, Liu M, Wang F, Bertin J, Núñez G. 2011. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. J Immunol 186: 7187-7194.
14. Chow MT, Sceneay J, Paget C, Wong CS, Duret H, Tschopp J, Möller A, Smyth MJ. 2012. NLRP3 suppresses NK cellmediated responses to carcinogen-induced tumors and metastases. Cancer Res 72: 5721-5732.
15. Corr SC, O'Neill LA. 2009. Genetic variation in Toll-like receptor signalling and the risk of inflammatory and immune diseases. J Innate Immun 1: 350-357.
16. Davis BK, Roberts RA, Huang MT, Willingham SB, Conti BJ, Brickey WJ, Barker BR, Kwan M, Taxman DJ, Accavitti- Loper MA, Duncan JA, Ting JP. 2011. Cutting edge: NLRC5-dependent activation of the inflammasome. J Immunol 186: 1333-1337.
17. Davoodi-Semiromi A, Wasserfall CH, Xia CQ, Cooper-DeHoff RM, Wabitsch M, Clare-Salzler M, Atkinson M. 2012. The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice. PLoS One 7: e36079.
18. Decker T, Kovarik P. 2000. Serine phosphorylation of STATs. Oncogene 19: 2628-2637.
19. Drexler SK, Bonsignore L, Masin M, Tardivel A, Jackstadt R, Hermeking H, Schneider P, Gross O, Tschopp J, Yazdi AS. 2012. Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis. Proc Natl Acad Sci U S A 109: 18384-1838.
20. Durant L, Watford WT, Ramos HL, Laurence A, Vahedi G, Wei L, Takahashi H, Sun HW, Kanno Y, Powrie F, O'Shea JJ. 2010. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 32: 605-615.
21. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. 2013. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 13: 759-771.
22. Ernst M, Najdovska M, Grail D, Lundgren-May T, Buchert M, Tye H, Matthews VB, Armes J, Bhathal PS, Hughes NR, Marcusson EG, Karras JG, Na S, Sedgwick JD, Hertzog PJ, Jenkins BJ. 2008. STAT3 and STAT1 mediate IL-11- dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest 118: 1727-1738.
23. Fessler MB, Rudel LL, Brown JM. 2009. Toll-like receptor signaling links dietary fatty acids to the metabolic syndrome. Curr Opin Lipidol 20: 379-385.
24. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Gwilliam R, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Gearry R, Glas J, Van Gossum A, Guthery SL, Halfvarson J, Verspaget HW, Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, Mowat C, Newman W, Panés J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PC, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D'Amato M, Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ, Parkes M. 2010. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 42: 1118-1125.
25. Fuentes E, Fuentes F, Vilahur G, Badimon L, Palomo I. 2013. Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome. Mediators Inflamm 2013: 136584.
26. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, Hsu D, Xu R, Harpaz N, Dannenberg AJ, Subbaramaiah K, Cooper HS, Itzkowitz SH, Abreu MT. 2007. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 133: 1869-1881.
27. Gharavi NM, Alva JA, Mouillesseaux KP, Lai C, Yeh M, Yeung W, Johnson J, Szeto WL, Hong L, Fishbein M, Wei L, Pfeffer LM, Berliner JA. 2007. Role of the Jak/STAT pathway in the regulation of interleukin-8 transcription by oxidized phospholipids in vitro and in atherosclerosis in vivo. J Biol Chem 282: 31460-31468.
28. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, Perfettini JL, Schlemmer F, Tasdemir E, Uhl M, Génin P, Civas A, Ryffel B, Kanellopoulos J, Tschopp J, André F, Lidereau R, McLaughlin NM, Haynes NM, Smyth MJ, Kroemer G, Zitvogel L. 2009. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15: 1170-1178.
29. Greenhill CJ, Gould J, Ernst M, Hertzog PJ, Mansell A, Jenkins BJ. 2011a. LPS hypersensitivity of gp130 mutant mice is independent of elevated haemopoietic TLR4 signaling. Immunol Cell Biol 90: 559-563.
30. Greenhill CJ, Rose-John S, Lissilaa R, Ferlin W, Ernst M, Hertzog PJ, Mansell A, Jenkins BJ. 2011b. IL-6 transsignaling modulates TLR4-dependent inflammatory responses via STAT3. J Immunol 186: 1199-1208.
31. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, Karin M. 2009. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitisassociated cancer. Cancer Cell 15: 103-113.
32. Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, Förster I, Farlik M, Decker T, Du Pasquier RA, Romero P, Tschopp J. 2011. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34: 213-223.
33. Guzzo C, Ayer A, Basta S, Banfield BW, Gee K. 2012. IL-27 enhances LPS-induced proinflammatory cytokine production via upregulation of TLR4 expression and signaling in human monocytes. J Immunol 188: 864-873.
34. Hansson GK, Hermansson A. 2011. The immune system in atherosclerosis. Nat Immunol 12: 204-212.
35. Higashimori M, Tatro JB, Moore KJ, Mendelsohn ME, Galper JB, Beasley D. 2011. Role of toll-like receptor 4 in intimal foam cell accumulation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 31: 50-57.
36. Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, Latz E, Fitzgerald KA. 2009. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458: 514-518.
37. Hoshi N, Schenten D, Nish SA, Walther Z, Gagliani N, Flavell RA, Reizis B, Shen Z, Fox JG, Iwasaki A, Medzhitov R. 2012. MyD88 signalling in colonic mononuclear phagocytes drives colitis in IL-10-deficient mice. Nat Commun 3: 1120.
38. Hu B, Elinav E, Huber S, Booth CJ, Strowig T, Jin C, Eisenbarth SC, Flavell RA. 2010. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci U S A 107: 21635-21640.
39. Jabara HH, McDonald DR, Janssen E, Massaad MJ, Ramesh N, Borzutzky A, Rauter I, Benson H, Schneider L, Baxi S, Recher M, Notarangelo LD, Wakim R, Dbaibo G, Dasouki M, Al-Herz W, Barlan I, Baris S, Kutukculer N, Ochs HD, Plebani A, Kanariou M, Lefranc G, Reisli I, Fitzgerald KA, Golenbock D, Manis J, Keles S, Ceja R, Chatila TA, Geha RS. 2012. DOCK8 functions as an adaptor that links TLRMyD88 signaling to B cell activation. Nat Immunol 13: 612-620.
40. Janowski AM, Kolb R, Zhang W, Sutterwala FS. 2013. Beneficial and detrimental roles of NLRs in carcinogenesis. Front Immunol 4: 370.
41. Jenkins BJ, Grail D, Nheu T, Najdovska M, Wang B, Waring P, Inglese M, McLoughlin RM, Jones SA, Topley N, Baumann H, Judd LM, Giraud AS, Boussioutas A, Zhu HJ, Ernst M. 2005. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat Med 11 (8): 845-852.
42. Kawai T, Akira S. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11: 373-384.
43. Kennedy CL, Najdovska M, Tye H, McLeod L, Yu L, Jarnicki A, Bhathal PS, Putoczki T, Ernst M, Jenkins BJ. 2014. Differential role of MyD88 and Mal/TIRAP in TLR2-mediated gastric tumourigenesis. Oncogene 33 (19): 2540-2546.
44. Kersse K, Bertrand MJ, Lamkanfi M, Vandenabeele P. 2011. NOD-like receptors and the innate immune system: coping with danger, damage and death. Cytokine Growth Factor Rev 22: 257-276.
45. Kidder BL, Yang J, Palmer S. 2008. Stat3 and c-Myc genomewide promoter occupancy in embryonic stem cells. PLoS One 3: e3932.
46. Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, Oh YT, Kim H, Rheey J, Nakano I, Lee C, Joo KM, Rich JN, Nam DH, Lee J. 2013a. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 23: 839-852.
47. Kim HS, Han MS, Chung KW, Kim S, Kim E, Kim MJ, Jang E, Lee HA, Youn J, Akira S, Lee MS. 2007. Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity 27: 321-333.
48. Kim JH, Bachmann RA, Chen J. 2009. Interleukin-6 and insulin resistance. Vitam Horm 80: 613-633.
49. Kim TH, Choi SE, Ha ES, Jung JG, Han SJ, Kim HJ, Kim DJ, Kang Y, Lee KW. 2013b. IL-6 induction of TLR-4 gene expression via STAT3 has an effect on insulin resistance in human skeletal muscle. Acta Diabetol 50: 189-200.
50. Krause CD, Pestka S. 2005. Evolution of the Class 2 cytokines and receptors, and discovery of new friends and relatives. Pharmacol Ther 106: 299-346.
51. Lee HK, Park DW, Bae JH, Kim HJ, Shin DG, Park JS, Lee JG, Lee SJ, Bae YS, Baek SH. 2012. RGS2 is a negative regulator of STAT3-mediated Nox1 expression. Cell Signal 24: 803-809.
52. Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Klöppel G, Yoshimura A, Reindl W, Sipos B, Akira S, Schmid RM, Algül H. 2011. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19: 456-469.
53. Li L, Xu T, Huang C, Peng Y, Li J. 2014. NLRC5 mediates cytokine secretion in RAW264.7 macrophages and modulated by the JAK2/STAT3 pathway. Inflammation 37 (3): 835-847.
54. Linossi EM, Babon JJ, Hilton DJ, Nicholson SE. 2013. Suppression of cytokine signaling: the SOCS perspective. Cytokine Growth Factor Rev 24: 241-248.
55. Liu X, Lee YS, Yu CR, Egwuagu CE. 2008a. Loss of STAT3 in CD4 + T cells prevents development of experimental autoimmune diseases. J Immunol 180: 6070-6076.
56. Liu X, Ukai T, Yumoto H, Davey M, Goswami S, Gibson 3rd FC, Genco CA. 2008b. Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. Atherosclerosis 196: 146-154.
57. Liu Y, Holdbrooks AT, De Sarno P, Rowse AL, Yanagisawa LL, McFarland BC, Harrington LE, Raman C, Sabbaj S, Benveniste EN, Qin H. 2014. Therapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis. J Immunol 192: 59-72.
58. Mansell A, Jenkins BJ. 2013. Dangerous liaisons between interleukin- 6 cytokine and toll-like receptor families: a potent combination in inflammation and cancer. Cytokine Growth Factor Rev 24: 249-256.
59. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. 2006. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nat Med 440: 237-241.
60. Marusawa H, Jenkins BJ. 2014. Inflammation and gastrointestinal cancer: an overview. Cancer Lett 345: 153-156.
61. McCormack W, Oshima M, Tan P, Jenkins BJ. 2012. Toll-like receptor 2: therapeutic target for gastric carcinogenesis. Oncotarget 3: 1260-1261.
62. Melkamu T, Kita H, O'Grady SM. 2013. TLR3 activation evokes IL-6 secretion, autocrine regulation of Stat3 signaling and TLR2 expression in human bronchial epithelial cells. J Cell Commun Signal 7: 109-118.
63. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. 2012. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 122: 143-159.
64. Mills KH. 2011. TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol 11: 807-822.
65. Minegishi Y, Karasuyama H. 2009. Defects in Jak-STATmediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency. Int Immunol 21: 105-112.
66. O'Shea JJ, Plenge R. 2012. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36: 542-550.
67. Oyamada A, Ikebe H, Itsumi M, Saiwai H, Okada S, Shimoda K, Iwakura Y, Nakayama KI, Iwamoto Y, Yoshikai Y, Yamada H. 2009. Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis. J Immunol 183: 7539-7546.
68. Pilati C, Amessou M, Bihl MP, Balabaud C, Nhieu JT, Paradis V, Nault JC, Izard T, Bioulac-Sage P, Couchy G, Poussin K, Zucman-Rossi J. 2011. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med 208: 1359-1366.
69. Ponomareva L, Liu H, Duan X, Dickerson E, Shen H, Panchanathan R, Choubey D. 2013. AIM2, an IFN-inducible cytosolic DNA sensor, in the development of benign prostate hyperplasia and prostate cancer. Mol Cancer Res 11: 1193-1202.
70. Rakoff-Nahoum S, Medzhitov R. 2009. Toll-like receptors and cancer. Nat Rev Cancer 9: 57-63.
71. Ramos HJ, Gale M, Jr. 2011. RIG-I like receptors and their signaling crosstalk in the regulation of antiviral immunity. Curr Opin Virol 1: 167-176.
72. Rhee SH, Jones BW, Toshchakov V, Vogel SN, Fenton MJ. 2003. Toll-like receptors 2 and 4 activate STAT1 serine phosphorylation by distinct mechanisms in macrophages. J Biol Chem 278: 22506-22512.
73. Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W, Study A3921063 Investigators. 2012. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 367: 616-624.
74. Santos-Sierra S, Deshmukh SD, Kalnitski J, Küenzi P, Wymann MP, Golenbock DT, Henneke P. 2009. Mal connects TLR2 to PI3Kinase activation and phagocyte polarization. EMBO J 28: 2018-2027.
75. Schroder K, Spille M, Pilz A, Lattin J, Bode KA, Irvine KM, Burrows AD, Ravasi T, Weighardt H, Stacey KJ, Decker T, Hume DA, Dalpke AH, Sweet MJ. 2007. Differential effects of CpG DNA on IFN-beta induction and STAT1 activation in murine macrophages versus dendritic cells: alternatively activated STAT1 negatively regulates TLR signaling in macrophages. J Immunol 179: 3495-3503.
76. Sedimbi SK, Hägglöf T, Karlsson MC. 2013. IL-18 in inflammatory and autoimmune disease. Cell Mol Life Sci 70: 4795-4808.
77. Serezani CH, Lewis C, Jancar S, Peters-Golden M. 2011. Leukotriene B4 amplifies NF-kB activation in mouse macrophages by reducing SOCS1 inhibition of MyD88 expression. J Clin Invest 121: 671-682.
78. Silver JS, Hunter CA. 2010. gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukoc Biol 88: 1145-1156.
79. Southworth T, Metryka A, Lea S, Farrow S, Plumb J, Singh D. 2012. IFN-g synergistically enhances LPS signalling in alveolar macrophages from COPD patients and controls by corticosteroid-resistant STAT1 activation. Br J Pharmacol 166: 2070-2083.
80. Stark GR, Darnell JE, Jr. 2012. The JAK-STAT pathway at twenty. Immunity 36: 503-514.
81. Strippoli R, Carvello F, Scianaro R, De Pasquale L, Vivarelli M, Petrini S, Bracci-Laudiero L, De Benedetti F. 2012. Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome. Arthritis Rheum 64: 1680-1688.
82. Stuart E, Buchert M, Putoczki T, Thiem S, Farid R, Elzer J, Huszar D, Waring PM, Phesse TJ, Ernst M. 2014. Therapeutic inhibition of Jak activity inhibits progression of gastrointestinal tumors in mice. Mol Cancer Ther 13: 468-474.
83. Stump KL, Lu LD, Dobrzanski P, Serdikoff C, Gingrich DE, Dugan BJ, Angeles TS, Albom MS, Ator MA, Dorsey BD, Ruggeri BA, Seavey MM. 2011. A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthritis Res Ther 13: R68-R82.
84. Stutz A, Golenbock DT, Latz E. 2009. Inflammasomes: too big to miss. J Clin Invest 119: 3502-3511.
85. Tye H, Jenkins BJ. 2013. Tying the knot between cytokine and toll-like receptor signaling in gastrointestinal tract cancers. Cancer Sci 104: 1139-1145.
86. Tye H, Kennedy CL, Najdovska M, McLeod L, McCormack W, Hughes N, Dev A, Sievert W, Ooi CH, Ishikawa TO, Oshima H, Bhathal PS, Parker AE, Oshima M, Tan P, Jenkins BJ. 2012. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell 22: 466-478.
87. Ungureanu D, Vanhatupa S, Grönholm J, Palvimo JJ, Silvennoinen O. 2005. SUMO-1 conjugation selectively modulates STAT1-mediated gene responses. Blood 106: 224-226.
88. van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B, ORAL Standard Investigators. 2012. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367: 508-519.
89. Wahren-Herlenius M, Dörner T. 2013. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 382: 819-831.
90. Wang X, Lupardus P, Laporte SL, Garcia KC. 2009. Structural biology of shared cytokine receptors. Annu Rev Immunol 27: 29-60.
91. Wei J, Yuan Y, Jin C, Chen H, Leng L, He F, Wang J. 2012. The ubiquitin ligase TRAF6 negatively regulates the JAKSTAT signaling pathway by binding to STAT3 and mediating its ubiquitination. PLoS One 7: e49567.
92. Wen H, Ting JP, O'Neill LA. 2012. A role for the NLRP3 inflammasome in metabolic diseases-did Warburg miss inflammation? Nat Immunol 13: 352-357.
93. White UA, Stephens JM. 2011. The gp130 receptor cytokine family: regulators of adipocyte development and function. Curr Pharm Des 17: 340-346.
94. Wieczorek M, Ginter T, Brand P, Heinzel T, Krämer OH. 2012. Acetylation modulates the STAT signaling code. Cytokine Growth Factor Rev 23: 293-305.
95. Woodgett JR. 2005. Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 17: 150-157.
96. Yang HZ, Cui B, Liu HZ, Mi S, Yan J, Yan HM, Hua F, Lin H, Cai WF, Xie WJ, Lv XX, Wang XX, Xin BM, Zhan QM, Hu ZW. 2009. Blocking TLR2 activity attenuates pulmonary metastases of tumor. PLoS One 4: e6520.
97. Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, Stark GR. 2007. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev 21: 1396-1408.
98. Yang J, Stark GR. 2008. Roles of unphosphorylated STATs in signaling. Cell Res 18: 443-451.
99. Yu CR, Lee YS, Mahdi RM, Surendran N, Egwuagu CE. 2012. Therapeutic targeting of STAT3 (signal transducers and activators of transcription 3) pathway inhibits experimental autoimmune uveitis. PLoS One 7: e29742.
100. Yu H, Pardoll D, Jove R. 2009. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9: 798-809.
101. Zaki MH, Lamkanfi M, Kanneganti TD. 2011. Inflammasomes and intestinal tumorigenesis. Drug Discov Today Dis Mech 8: e71-e78.
102. Zhao R, Zhou H, Su SB. 2013. A critical role for interleukin-1b in the progression of autoimmune diseases. Int Immunopharmacol 17: 658-669.